| Cat. No. |
Product Name |
Information |
| PC-Ab1108 |
Sabatolimab
|
Binds and blocks the interaction TIM3/PtdSer (Kd=0.16 nM, PtdSer Blocking IC50=6.4 nM) , restore effector T cell activity to promote antitumor immunity by altering myeloid cells in tumor microenvironment. TIM-3 may synergize with PD-1 blockade by enhancing or altering the innate immune response and may form part of a resistance mechanism to PD-1 blockade.. |
| PC-Ab1107 |
TSR-033
|
TSR-033 is a high affinity humanized IgG4, κ mAb that specifically binds LAG-3 and blocks the interaction between LAG-3 and its ligand MHC Class II. TSR-033 serves as a functional antagonist, enhancing in vitro T-cell activation both in mixed lymphocyte reactions and staphylococcal enterotoxin B-driven stimulation assays. In a humanized mouse non-small cell lung carcinoma model, TSR-033 boosted the antitumor efficacy of PD-1 monotherapy, with a concomitant increase in immune activation.. |
| PC-Ab1106 |
Rovalpituzumab
|
Rovalpituzumab is the antibody part of Rovalpituzumab tesirine (Rova-T). Delta-like protein 3 (DLL3) is a transmembrane protein that belongs to the Delta/Serrate/Lag-2 (DSL) family of Notch ligands. Rovalpituzumab tesirine (SC16LD6.5) is an antibody-drug conjugate that targets delta-like protein 3 (DLL3) and was initially developed for small cell lung cancer.. |
| PC-Ab1105 |
Oleclumab
|
Oleclumab (MEDI 9447) is a human IgG1 lambda mAb with a triple mutation in the heavy chain constant region for reduced effector function. Oleclumab binds to cluster of differentiation 73 (ecto-5'-nucleotidase) (CD73) and inhibits CD73-associated ectonucleotidase activity, thereby inhibiting the CD73-mediated production of immunosuppressive adenosine. Extracellular adenosine contributes to the immunosuppressive effects of both regulatory T cells and myeloid derived suppressor cells, among others. |
| PC-Ab1104 |
Sintilimab
|
Sintilimab (IBI 308) is a type of immunoglobulin G4 monoclonal antibody, which binds to PD-1 molecules on the surface of T-cells, blocks the PD-1 / PD-Ligand 1 (PD-L1) pathway, and reactivates T-cells to kill cancer cells. . |
| PC-Ab1103 |
Toripalimab
|
Toripalimab (JS 001, SO-001, TAB-001) is an anti-PD-1 monoclonal antibody developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, and for enhanced receptor endocytosis function. Blocking PD-1 interactions with PD-L1 and PD-L2 is thought to recharge the immune system’s ability to attack and kill tumor cells.. |
| PC-Ab1102 |
Leramilimab
|
LAG525 (Leramilimab) is a high-affinity, ligand-blocking monoclonal antibody that targets LAG3 and blocks interaction with MHC class II molecules, leading to enhanced T-cell response to tumor cells and decreased tumor growth. LAG525 blocks binding of LAG-3, a negative regulator of T-cell signalling, to MHC class II on tumour cells, which renders the tumour microenvironment less immunosuppressive, and may therefore enhance the activity of PD-1 blockade.. |
| PC-Ab1101 |
Nesvacumab
|
Nesvacumab (REGN910) is a fully human immunoglobulin G1 (IgG1) monoclonal antibody that specifically binds and inactivates the Tie2 receptor ligand vascular growth factor called angiopoietin2 (Ang2) with high affinity (Kd=24 pM), but shows no binding to Ang1.. |
| PC-Ab1100 |
Palivizumab
|
Palivizumab (MEDI-493) is a monoclonal antibody to the RSV F protein that inhibits binding of the virus to cellular receptors. This reduces viral activity and cell-to-cell transmission, and blocks the fusion of infected cells. Palivizumab is directed at an epitope in the A antigenic site of the 'F' protein on the surface of RSV. Palivizumab binds to this epitope, which is highly conserved among different RSV isolates.. |
| PC-Ab1099 |
Dacetuzumab
|
Dacetuzumab (SGN-40, huS2C6) is a humanized anti-CD40 monoclonal antibody that specifically binds to and works against a molecule called a CD40 receptor. Dacetuzumab has been used in trials studying the treatment of Multiple Myeloma, Non-Hodgkin Lymphoma, Leukemia, Lymphocytic, Chronic, and Lymphoma, Large B-Cell, Diffuse. It is a humanized anti-CD40 antibody and induces cytotoxicity in human multiple myeloma cells. Dacetuzumab demonstrated antitumor activity in relapsed/refractory diffuse large |
| PC-Ab1098 |
Gemtuzumab
|
Gemtuzumab is a biosimilar directed against the extracellular domain of CD33. This product constitutes the immunogen used for the anti-Idiotype catalog numbers MAB9617 and MAB96171. The biotinylated antibody (catalog number FAB9635B) can be used in flow cytometry or various assay format to measure Siglec‑3/CD33 expression and can be detected by conjugated streptavidin. Gemtuzumab is the antibody part of Gemtuzumab ozogamicin.. |
| PC-Ab1097 |
Elotuzumab
|
Elotuzumab (HuLuc63) is a humanized mAb that targets the cell surface adhesion molecule CS1, which is selectively expressed on more than 95% of plasma cells and has little to no expression on normal tissues. Elotuzumab binds to CS1 on MM cells and NK cells recognize the Fc region of antibody by CD16 and thus mediate ADCC (Antibody-dependent cell-mediated cytotoxicity) against MM cells. In addition, binding of Elotuzumab on CS1 on the NK cells activate natural cytotoxicity of NK cells. Activation |
